Erratum: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer (Annals of Oncology (2005) vol. 16 (1639-1645)

H. Oettle, D. Richards, R. K. Ramanathan, J. L. van Laethem, M. Peeters, M. Fuchs, A. Zimmermann, W. John, D. Von Hoff, M. Arning, H. L. Kindler, Jen Shi Chen, Yee Chao

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Number of pages1
JournalAnnals of Oncology
Volume17
Issue number3
DOIs
StatePublished - Mar 2006

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Oettle, H., Richards, D., Ramanathan, R. K., van Laethem, J. L., Peeters, M., Fuchs, M., Zimmermann, A., John, W., Von Hoff, D., Arning, M., Kindler, H. L., Chen, J. S., & Chao, Y. (2006). Erratum: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer (Annals of Oncology (2005) vol. 16 (1639-1645). Annals of Oncology, 17(3). https://doi.org/10.1093/annonc/mdl032